ORGO
Organogenesis Holdings Inc.
$2.40
-0.06 (-2.44%)
At close · Jul 10
Market Cap
$308.82M
Shares
128,674,548
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$564.17M
+17%
FY2025
Net Income
$37.03M
+4201%
FY2025
Gross Margin
75.99%
+0.6pp
FY2024
Operating Margin
7.92%
+8.2pp
FY2025
Diluted EPS
$0.15
+1600%
FY2025
Operating Cash Flow
-$10.31M
-172.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $514.7M | $564.17M | $482.04M | $433.14M | $450.89M | $467.36M | $338.3M | $260.98M | $193.45M | $198.51M | $138.73M | |
| $110.77M | — | $115.74M | $106.48M | $105.02M | $114.2M | $87.32M | $75.95M | $68.81M | $61.22M | $48.2M | |
| $347.99M | — | $366.3M | $326.66M | $345.87M | $353.16M | $250.98M | $185.03M | $124.64M | $137.29M | $90.53M | |
| — | — | 75.99% | 75.42% | 76.71% | 75.57% | 74.19% | 70.9% | 64.43% | 69.16% | 65.26% | |
| $49.06M | $44.54M | $50.27M | $44.38M | $39.76M | $30.74M | $20.09M | $14.8M | $10.74M | $9.07M | $6.28M | |
| $318.91M | $326.24M | $294.51M | $269.75M | $283.81M | $250.2M | $204.19M | $200.09M | $161.96M | $133.72M | $93.03M | |
| $8.19M | $3.32M | $3.4M | $4.92M | $4.88M | $4.95M | $3.75M | $6.04M | $3.67M | $2.04M | $1.62M | |
| — | $15.27M | $13.62M | $10.45M | $5.85M | — | — | — | — | — | — | |
| — | $516K | $0 | $3.8M | $2.27M | $4.7M | $618K | — | — | — | — | |
| $512.16M | $519.48M | $483.33M | $420.62M | $323.57M | $280.94M | $224.28M | $214.89M | $176.2M | $142.78M | $99.31M | |
| $2.55M | $44.69M | -$1.28M | $12.53M | $22.3M | $72.22M | $26.7M | -$29.85M | -$51.56M | -$5.49M | -$8.78M | |
| — | 7.92% | -0.27% | 2.89% | 4.95% | 15.45% | 7.89% | -11.44% | -26.65% | -2.77% | -6.33% | |
| — | $59.97M | $12.34M | $22.97M | $28.15M | — | — | — | — | — | — | |
| -$1.7M | -$2.28M | $1.54M | $2.19M | $2.01M | $7.24M | $11.28M | $9M | $10.79M | $8.01M | $5.63M | |
| $64K | — | — | — | — | — | — | — | $64K | $129K | $153K | |
| $1.73M | $2.28M | -$1.52M | -$2.13M | -$2.02M | -$9.13M | -$8.94M | -$8.71M | -$13.19M | -$9.06M | -$5.93M | |
| $4.28M | $46.97M | -$2.81M | $10.39M | $20.28M | $63.09M | $17.76M | -$38.56M | -$64.75M | -$14.55M | -$14.7M | |
| $1.56M | $9.94M | -$3.67M | $5.45M | $4.75M | -$31.12M | $530K | $150K | $84K | -$7.03M | $65K | |
| $2.72M | $37.03M | $861K | $4.95M | $15.53M | $94.2M | $17.23M | -$38.71M | -$64.83M | -$8.39M | -$16.99M | |
| — | 6.56% | 0.18% | 1.14% | 3.44% | 20.16% | 5.09% | -14.83% | -33.51% | -4.23% | -12.24% | |
| — | — | — | — | — | — | — | — | — | $863K | $2.22M | |
| -$14.55M | $20.02M | -$937K | $4.95M | $15.53M | $94.9M | $17.23M | -$39.28M | -$64.83M | -$8.81M | -$208.7K | |
| USD/shares | — | $0.16 | -$0.01 | $0.04 | $0.12 | $0.73 | $0.16 | -$0.42 | -$0.94 | — | — |
| USD/shares | — | $0.15 | -$0.01 | $0.04 | $0.12 | $0.70 | $0.15 | -$0.42 | -$0.94 | — | — |
| shares | — | 126.74M | 131.67M | 131.23M | 130.07M | 128.33M | 107.74M | 92.84M | 69.32M | 63.88M | 63.2M |
| shares | — | 130.25M | 131.67M | 132.75M | 132.38M | 133.66M | 111.36M | 92.84M | 69.32M | 63.88M | 63.2M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2024: $25.48M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Drug Manufacturers - Specialty & Generic median 2.09×
EV/EBIT
—
Drug Manufacturers - Specialty & Generic median 33.82×
P/E (TTM)
—
Drug Manufacturers - Specialty & Generic median 20.88×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|
| Product | $563,030,000 | $482,043,000 | $433,140,000 | — | — | — | — |
| Grant | $1,139,000 | $0 | $0 | — | — | — | — |
| Advanced Wound Care | — | $453,639,000 | $405,514,000 | $422,231,000 | $430,237,000 | $294,624,000 | $220,744,000 |
| Surgical and Sports Medicine | — | $28,404,000 | $27,626,000 | $28,662,000 | $37,122,000 | $43,674,000 | $40,237,000 |